Mark Baglin

Mark joined as Chief Commercial Officer in November 2021, and brings substantial experience of Commercial and Franchise leadership in the Biopharmaceutical industry which he will bring to bear in building and leading global commercial teams towards launch and beyond in the rare fungal disease space. Prior to joining F2G, Mark was SVP, Head of Marketed Products at Alnylam, responsible for all in-line and late-stage franchise and program teams in Rare Disease spaces. Prior to that, he was VP, Head of Global Marketing and Commercial Strategy, building and leading the Marketing and Market Access teams that executed three global launches. Before joining Alnylam, Mark was Head of Shire’s $1.5bn HAE franchise, which he helped build over 7 years in roles of increasing responsibility, including two external acquisitions. Prior to joining Shire, Mark gained experience with a number of small and large Pharma and Medical device companies, in local and global commercial roles. Mark holds a Bachelor of Commerce (B.Com) degree from the University of Birmingham, UK.